Capstan has developed a catheter-based therapy for cardiac valve replacements. Supply: Capstan Medical
Capstan Medical at the moment mentioned it has efficiently accomplished its first in-human, robot-assisted transcatheter mitral valve replacements. The Santa Cruz, Calif.-based firm claimed that it was “the primary time a minimally invasive robotic structural coronary heart platform has been utilized in medical follow, efficiently delivering a novel mitral valve into two human sufferers.”
Dr. Gonzalo Martinez carried out the minimally invasive procedures at Hospital Clínico Universidad Católica in Santiago, Chile. Martinez, M.D., MPhil, is director of the Endovascular Remedy Heart at Pontifical Catholic College of Chile. He was supported by Dr. Santiago Garcia, director of the Structural Coronary heart Program at The Christ Hospital in Cincinnati, Ohio.
“We’re honored to pioneer this innovation that has the potential to rework how we deal with coronary heart valve illness, particularly for sufferers who aren’t candidates for standard surgical procedure,” mentioned Martinez. “The Capstan know-how exceeded our expectations even in these early instances.”
New cardiac choices may deal with extra sufferers
Coronary heart illness stays the main reason behind demise on the planet, claiming a life each 33 seconds within the U.S. alone, in accordance with the Facilities for Illness Management. At present, greater than 7 million folks within the U.S. have coronary heart valve illness, a fancy situation made up primarily of dysfunctional mitral and tricuspid valves.
Present therapy choices, sometimes by open-heart surgical procedure, aren’t viable for many sufferers, and current catheter-based choices have excessive charges of affected person exclusion, mentioned Capstan Medical. The corporate mentioned it seeks to beat present therapy limitations by bringing collectively novel heart-valve implants and superior catheter know-how, totally enabled by a robotic platform, to deal with a broader set of sufferers.
“These profitable first-in-human instances symbolize a big leap ahead in structural coronary heart intervention,” mentioned Garcia. “I’ve labored with quite a few applied sciences, however this essentially adjustments what’s attainable within the therapy of valvular coronary heart illness.”
“The robotic platform offered unprecedented catheter stability and management, attaining optimum implant positioning,” he added. “Each sufferers had elimination of their mitral regurgitation, with unobstructed left ventricular outflow tracts. [They] had been launched residence after a couple of days feeling significantly better than how they arrived. That is the enabling know-how the structural coronary heart discipline has been ready for.“
Register now so you do not miss out!
Capstan Medical continues on plan
Based in 2020, Capstan Medical mentioned it “is creating a brand new normal for minimally invasive, coronary heart valve intervention.” The firm is creating a set of next-generation coronary heart valve implants and a first-of-its-kind catheter-based robotic supply platform.
Capstan raised $110 million in Sequence C funding in December 2024. It mentioned it plans to proceed to execute on its plan for medical and growth work main to imminent trials.
“At present marks a pivotal second within the evolution of structural coronary heart remedy,” mentioned Maggie Nixon, CEO of Capstan Medical. “Seeing the capabilities of our system, catheter, and implant come collectively to ship groundbreaking human instances validates years of analysis, growth, and unwavering dedication from our staff. This achievement demonstrates the potential of our know-how to reshape the way forward for structural coronary heart procedures.”